/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Vericel Corporation Share Price Today: Live Updates & Key Insights

Vericel Corporation share price today is $32.11, up -2.34%. The stock opened at $32.21 against the previous close of $32.88, with an intraday high of $32.9825 and low of $31.71.

Vericel Corporation Share Price Chart

style
pb-0

Vericel Corporation

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Vericel Corporation Share Price Performance

$32.11 -0.0234(-2.34%) VCEL at 13 Mar 2026 03:43 PM Biotechnology
Lowest Today 31.71
Highest Today 32.9825
Today’s Open 32.21
Prev. Close 32.88
52 Week High 48.75
52 Week Low 29.24
Day’s Range: Low 31.71 High 32.9825
52-Week Range: Low 29.24 High 48.75
1 day return -
1 Week return -4.19
1 month return -10.53
3 month return -11.81
6 month return +2.61
1 year return -29.05
3 year return +8.64
5 year return -32.0
10 year return -

Vericel Corporation Institutional Holdings

BlackRock Inc 14.91

Vanguard Group Inc 7.06

iShares Core S&P Small-Cap ETF 6.05

State Street Corp 5.53

Conestoga Capital Advisors, LLC 4.44

William Blair Investment Management, LLC 4.38

FMR Inc 4.28

Geneva Capital Management 3.60

Congress Asset Management Company, LLP 3.28

Vanguard Total Stock Mkt Idx Inv 3.14

Conestoga Small Cap Investors 3.02

GW&K Investment Management, LLC 2.54

BNP Paribas Investment Partners SA 2.50

State Street® SPDR® S&P® Biotech ETF 2.48

iShares Russell 2000 ETF 2.40

Geode Capital Management, LLC 2.39

Loomis, Sayles & Company LP 2.08

Champlain Investment Partners, LLC 2.03

Royal Bank of Canada 2.00

Champlain Small Company Fund, LLC 1.88

Congress Small Cap Growth Institutional 1.87

Federated Hermes Inc 1.76

Capital Research Global Investors 1.68

Brown Capital Management, LLC 1.64

Brown Capital Mgmt Small Co Inv 1.61

Dimensional Fund Advisors, Inc. 1.61

BNP Paribas US Small Cap ClassicC 1.53

BNP Paribas Health Cr Innovtr Cl Cap 1.48

Amvescap Plc. 1.47

Allspring Global Investments Holdings, LLC 1.38

Conestoga Small Cap Growth 1.22

Loomis Sayles Small Cap Growth Instl 1.13

Nationwide Geneva Small Cap Gr Instl Svc 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Fidelity Small Cap Growth 1.00

William Blair SMID Core CIT 2 0.99

Fidelity Small Cap Index 0.97

Champlain Small Company Adv 0.94

State Street SPDR Port S&P 600 Sm CpETF 0.93

iShares S&P Small-Cap 600 Growth ETF 0.85

Vericel Corporation Market Status

Strong Buy: 7

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Vericel Corporation Fundamentals

Market Cap 1669.10 M

PB Ratio 4.7065

PE Ratio 102.75

Enterprise Value 1627.97 M

Total Assets 487.97 M

Volume 929159

Vericel Corporation Company Financials

Annual Revenue FY23:185214000 185.2M, FY22:164365000 164.4M, FY21:156184000 156.2M, FY20:124179000 124.2M, FY19:117850000 117.9M

Annual Profit FY23:125318000 125.3M, FY22:109788000 109.8M, FY21:106025000 106.0M, FY20:84228000 84.2M, FY19:80279000 80.3M

Annual Net worth FY23:-10253000 -10.3M, FY22:-16709000 -16.7M, FY21:-7471000 -7.5M, FY20:2864000 2.9M, FY19:-7909000 -7.9M

Quarterly Revenue Q3/2025:67503000 67.5M, Q2/2025:63240000 63.2M, Q1/2025:52598000 52.6M, Q3/2024:57905000 57.9M, Q2/2024:52662000 52.7M

Quarterly Profit Q3/2025:49585000 49.6M, Q2/2025:46613000 46.6M, Q1/2025:36273000 36.3M, Q3/2024:41653000 41.7M, Q2/2024:36601000 36.6M

Quarterly Net worth Q3/2025:5074000 5.1M, Q2/2025:-553000 -0.6M, Q1/2025:-11246000 -11.2M, Q3/2024:-901000 -0.9M, Q2/2024:-4682000 -4.7M

About Vericel Corporation & investment objective

Company Information Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 398

Industry Biotechnology

CEO Mr. Dominick C. Colangelo Esq.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow